CoLucid gets $25M

CompanyAmount/RoundLead InvestorsDescription

CoLucid CoLucid Pharmaceuticals
Care Capital

The financing will be used to develop COL-144, a migraine compound, and to advance preclinical pipeline candidates that target neurological and psychiatric disorders.

Immune Design
Alta Partners, The Column Group and Versant Ventures

The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies.

Limerick BioPharma
South San Francisco
Arch Venture Partners, Sevin Rosen Funds and Altitude Funds

Limerick BioPharma will advance its work on the bioavailability of drugs.

CoLucid gets $25M